
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova's revenue has shown significant growth, with sales rising by 29% to $803 million in 2024, and management projecting further sales increase to between $940 million and $955 million. The company benefits from its diverse portfolio, primarily in cardiopulmonary solutions and neuromodulation devices, capturing roughly half of its revenue from the US market and a substantial portion from Europe. Additionally, expectations of increasing market share for its aura6000 device, with potential sales reaching up to $280 million by 2029 in a favorable scenario, bolster the optimism for LivaNova's future performance.
Bears say
LivaNova is facing a negative outlook primarily due to anticipated revenue growth slowing to low-single digits, driven by persistent challenges in its Neuromodulation and Cardiovascular segments. The company is also grappling with operating margin contraction and below-consensus earnings expectations, further emphasizing its financial difficulties. Additionally, risks, including potential failure to gain FDA approval for the aura6000 device and slower-than-expected growth in its core businesses, contribute to the unfavorable financial projections.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares